Back to Search Start Over

SAR exploration of the non-imidazole histamine H 3 receptor ligand ZEL-H16 reveals potent inverse agonism.

Authors :
Wágner G
Mocking TAM
Ma X
Slynko I
Da Costa Pereira D
Breeuwer R
Rood NJN
van der Horst C
Vischer HF
de Graaf C
de Esch IJP
Wijtmans M
Leurs R
Source :
Archiv der Pharmazie [Arch Pharm (Weinheim)] 2023 Jan; Vol. 356 (1), pp. e2200451. Date of Electronic Publication: 2022 Oct 30.
Publication Year :
2023

Abstract

Histamine H <subscript>3</subscript> receptor (H <subscript>3</subscript> R) agonists without an imidazole moiety remain very scarce. Of these, ZEL-H16 (1) has been reported previously as a high-affinity non-imidazole H <subscript>3</subscript> R (partial) agonist. Our structure-activity relationship analysis using derivatives of 1 identified both basic moieties as key interaction motifs and the distance of these from the central core as a determinant for H <subscript>3</subscript> R affinity. However, in spite of the reported H <subscript>3</subscript> R (partial) agonism, in our hands, 1 acts as an inverse agonist for Gα <subscript>i</subscript> signaling in a CRE-luciferase reporter gene assay and using an H <subscript>3</subscript> R conformational sensor. Inverse agonism was also observed for all of the synthesized derivatives of 1. Docking studies and molecular dynamics simulations suggest ionic interactions/hydrogen bonds to H <subscript>3</subscript> R residues D114 <superscript>3.32</superscript> and E206 <superscript>5.46</superscript> as essential interaction points.<br /> (© 2022 The Authors. Archiv der Pharmazie published by Wiley-VCH GmbH on behalf of Deutsche Pharmazeutische Gesellschaft.)

Details

Language :
English
ISSN :
1521-4184
Volume :
356
Issue :
1
Database :
MEDLINE
Journal :
Archiv der Pharmazie
Publication Type :
Academic Journal
Accession number :
36310109
Full Text :
https://doi.org/10.1002/ardp.202200451